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Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as an oncoprotein
and a molecular and immunogenic target. Despite the success of targeted therapy using tyrosine kinase inhibitors
(TKIs), CML remains largely incurable, most likely due to the treatment resistance of leukemic stem cells. Several
immunotherapies have been developed for CML in different stages and relapse after allogeneic stem cell
transplantation. In the this review, several specific immunotherapeutic approaches for CML, including vaccination
and adoptive cellular immunotherapy, are discussed along with results from clinical trials, and the value of such
immunotherapies in the era of imatinib and leukemia-associated antigens (LAAs), which are capable of inducing
specific T cell responses and are appropriate target structures for the immunological targeting of CML cells, are
also summarized.
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Chronic myelogenous leukemia (CML) is a clonal mye-
loproliferative hematopoietic stem cell disorder that is
characterized by a t(9;22) translocation, which results in
the expression of BCR-ABL fusion oncoproteins that are
unique to the leukemic cells, necessary for oncogenesis,
and potentially immunogenic [1].
The BCR-ABL tyrosine kinase inhibitor imatinib is
highly effective for first-line CML treatment and is
increasingly used in patients with residual disease or re-
lapse after allogeneic hematopoietic stem cell transplant-
ation (allo-HSCT). Despite the success of imatinib and
other tyrosine kinase inhibitors (TKIs), CML remains
largely incurable, and this is likely due to the treatment
resistance of leukemic stem cells, which are responsible
for rapid disease relapse after the discontinuation of
therapy. How to treat patients with CML who are resist-
ant to BCR-ABL tyrosine kinase inhibitors is an import-
ant and urgent issue for clinical hematology. Based on
experimental research exploring the imatinib resistance* Correspondence: yangqiuli@hotmail.com
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reproduction in any medium, provided the ormechanism in CML cells, second-generation TKIs were
developed. Dasatinib and nilotinib, two newer drugs
with higher potency than imatinib against BCR-ABL and
activity against most imatinib-resistant BCR-ABL muta-
tions, have demonstrated superior efficacy compared
with imatinib for first-line chronic-phase CML treatment
in randomized phase III trials [2,3]. However, because
successful treatment of a portion of patients with CML
using allo-HSCT suggests the importance of immune
mechanisms in eliminating leukemic cells including
leukemia stem cells, TKI administration or HSCT may
be combined with vaccination to cure patients with
CML [4].
The history of CML immunotherapetic strategies
begins as early as 1975 when patients with CML
received repeated intradermal BCG-cultured cell mix-
ture injections or were vaccinated with BCG alone in a
clinical immunotherapy trial, and data from cases in
which intermittent busulfan therapy was used provided
evidence suggesting that immunotherapy prolonged
the unmaintained remission of one-third of patients [5].
Today, in the molecular biology and immunology
era, increasing effective and specific immunotherapies
involving vaccination or adoptive cellular immunother-
apy are used.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In patients with leukemia, T cell function becomes sup-
pressed with disease progression. Such immune dysfunc-
tion, which has been demonstrated in many patients
with leukemia, may be due to a disorder in the thymic
output function, the abnormal expression of the T cell
receptor (TCR) repertoire and, in part, abnormal TCR
signal transduction, possibly through altered CD3 gene
expression [6-12]. In de novo CML, decreased levels of
recent thymic emigrants in CD4+ and CD8 + T cells may
underlie the persistent immunodeficiency found in
patients. Restricted TCR Vβ repertoire expression indi-
cates T cell immunodeficiency in patients, although
clonally expanded T cells suggest a specific immune re-
sponse to leukemia-associated antigens [9,13]. A defi-
ciency in the level of CD3 gene expression may be a
characteristic of lower T cell activation [6-8]. The ab-
sence of the TCRζ chain not only influences the level of
TCR expression on the cell membrane and the number
of single positive (CD4+ or CD8+) circulating T cells, it
also impairs the proliferative response and mature T cell
activation level. T cells from patients with CML are
functionally impaired, and this is indicated by decreased
TCRζ chain expression [6,9,14].
Moreover, imatinib impairs CD8+ T cells specifically
directed against leukemia-associated antigen function
in vitro; therefore, clinical imatinib administration
may result in reduction of the efficacy of the graft-
versus-leukemia effect or other T-cell-based immuno-
therapies [15].
In contrast, it has been demonstrated that patients
with CML possess T cells capable of recognizing autolo-
gous tumor cells, and clonally expanded T cells were
identified in some TCR subfamilies in the peripheral
blood of patients with CML, which display specific anti-
leukemia cytotoxicity such as WT1 or BCR-ABL-specific
cytotoxic T cells (CTLs), indicating that specific anti-
leukemic T cells could be generated in vivo [13,16,17].
This finding suggested that the host could have a spe-
cific immune response to leukemia-associated antigens
despite T cell immunodeficiency. Several clinical obser-
vations, which were supported by experimental data, in-
dicate the presence of CML-specific T cells.
Leukemia-specific T cells are regularly detected in
patients with CML and may be involved in the immuno-
logical control of the disease. However, recent findings
demonstrated that leukemia-specific CTLs maintain only
limited cytotoxic activity, do not produce interferon-γ or
tumor necrosis factor-α, and do not expand after resti-
mulation. Because CML-specific CTLs were character-
ized by the high expression of programmed death 1
(PD-1) and CML cells expressed PD-ligand 1 (PD-L1)
[18], this phenomenon was found not only in a CML
mouse model but in patients with CML as well [19].PD-1 is another inhibitory T-cell receptor that is
engaged by its two known ligands PD-L1 (also known as
B7-H1 or CD274) and PD-L2 (also known as B7-DC or
CD273) primarily within the tumor microenvironment,
and increased PD-1 and PD-L1 expression appeared to
increased immune suppressive signals, which was related
to inhibition of the effector phase of T cell responses
and reduced antitumor activity [20].
Increased understanding of the molecular biology and
immunology of CML and highly specific immune
responses will lead to novel and improved immunother-
apeutic strategies for patients with CML.
Vaccines
Despite the considerable successes that have been
achieved for CML treatment, a cure for this disease can
only be obtained via the current treatments in a minority
of patients. During the past decade, considerable
progress has been made in the understanding of the
immunology of CML, which has raised hopes that
this disease may be curable by supplementing the
current targeted chemotherapy with immunotherapeutic
approaches. More than ten small-scale clinical trials have
been performed using experimental vaccines predomin-
antly based on the p210 BCR-ABL fusion protein [21],
and other attractive targets include the Wilms' tumor 1
(WT1) antigen and the PR1 epitope from proteinase 3, a
granule protein overexpressed in CML. In clinical trials,
peptide vaccination appears safe and undoubtedly results
in clinical effects.
BCR-ABL-derived peptide vaccines
Nearly all patients with CML express the BCR-ABL fu-
sion product on their leukemia cells. The chimeric p210
BCR-ABL fusion protein, comprising products of either
the b2a2 or b3a2 exon junction, represents a potentially
immunogenic tumor-specific antigen. Despite the intra-
cellular location of this oncogenic fusion protein, it has
been shown that peptides derived from its junctional re-
gion can be recognized by human T cells obtained from
patients with CML or normal donors and can elicit a
BCR-ABL peptide-specific T cell immune response.
The first evidence of a cytolytic human immune re-
sponse against CML BCR-ABL oncogene-derived pep-
tides was described by Bocchia et al. who demonstrated
that peptides derived from amino acid sequences cross-
ing the b3a2 fusion breakpoint in p210 elicit class I
restricted cytotoxic T cells and class II-mediated T cell
proliferation, respectively, in vitro [22,23]. Thus, such
sequences may comprise definitive tumor-specific anti-
gens in a peptide-based vaccine and provide a rationale
for developing peptide-based vaccines for CML.
The different BCR-ABL breakpoint peptide vaccines were
evaluated in numerous clinic trials. Pinilla-Ibarz J et al. were
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ation strategy [24]. The vaccine was well tolerated and
elicited specific immune responses in patients with
CML. In a phase II trial from the same group, 14
patients with chronic phase CML were vaccinated 5
times. Immunological and clinical effects were detected;
however, CTLs were not identified [24,25]. Thus, in
phase I and II trials, a tumor-specific BCR-ABL derived
peptide vaccine could be safely administered to patients
with chronic phase CML and elicit BCR-ABL peptide-
specific CD4 immunity. However, CD8 responses
were limited. Therefore, one strategy to circumvent this
poor immunogenicity is to design synthetic immuno-
genic analog peptides that cross-react with native
peptides (i.e., a heteroclitic response). A number of syn-
thetic peptides derived from CML junctional sequences
(i.e., p210/b3a2 or p210/b2a2) in which single and
double amino acid substitutions were introduced
at key HLA-A0201 binding positions were screened
for eliciting HLA restricted, peptide-specific CTL re-
sponses using CD3+ T cells from several A0201 donors
and patients with CML [26].
A significant BCR-ABL vaccination effect was
described in a 63-year-old woman with CML relapse
after interferon (IFN)-α treatment who achieved a
complete cytogenetic response for 6 years. The patient
was treated with a therapeutic vaccine comprising an
immunogenic 25-mer b2a2 breakpoint-derived peptide
(CMLb2a2-25) with binding properties for several HLA-
DR molecules. After nine vaccine boosts, the patient
developed an adequate b2a2-25 peptide-specific CD4+ T
cell response, and the BCR-ABL1 transcript began
declining in the peripheral blood. At the last evaluation
i.e., 39 months since the vaccinations commenced,
the patient is in complete molecular response with
an undetectable level of BCR-ABL1 transcript in the
peripheral blood and bone marrow. She continues
to receive a vaccine boost every 3 months as her only
treatment [27].
Recently, BCR-ABL peptides were used as combin-
ation immunotherapy in imatinib-treated patients with
CML. BCR-ABL peptide vaccination may improve the
control of CML, particularly in patients responding well
to imatinib. A trial with 19 imatinib-treated patients
with CML in the first chronic phase were vaccinated
with BCR-ABL peptides spanning the e14a2 fusion junc-
tion, and 14 of the 19 patients developed T cell
responses to BCR-ABL peptides. The development of an
anti-BCR-ABL T cell response correlated with a subse-
quent decrease in BCR-ABL transcripts. Of the 14
patients in MCR at baseline, 13 developed at least a 1
log decrease in BCR-ABL transcripts [28]. Similar results
were reported in a phase II trial in which 10 patients
who had received imatinib for a median of 62 monthswere enrolled [29]. These data suggested that a
vaccination-related transient disruption in immune
tolerance may contribute to a reduction in BCR-ABL
transcripts, and this BCR-ABL peptide vaccine may tran-
siently improve the molecular response in a subset of
patients with CML.
Although most patients with CML achieve clinically
relevant hematologic and cytogenetic responses to imati-
nib, CML cells with a BCR-ABL mutation (T315I) confer
drug resistance to imatinib, dasatinib and nilotinib treat-
ment; therefore, the development of a vaccine expressing
the T315I-mutated BCR-ABL antigen to stimulate an
anti-BCR-ABL (T315I) immune response appears to be
more important. A recombinant yeast-based vaccine
expressing the T315I-mutated BCR-ABL antigen was
demonstrated to significantly reduce or eliminate BCR-
ABL (T315I) leukemia cells from the peripheral blood of
immunized animals and extended leukemia-free survival
in a murine BCR-ABL + leukemia model [30]. Thus, this
may be a potential vaccine for patients with CML.
WT1 vaccines
WT1 is an oncogenic protein expressed by the Wilms'
tumor gene that is overexpressed in the majority of
acute myelogenous leukemias (AMLs) and CML. WT1
expression in progenitor cells is minimal or absent, and
the limited WT1 tissue expression in adults suggests
that WT1 may be a leukemia therapy target. In mice,
WT1 vaccines elicit specific immune responses without
evidence of tissue damage [31]. Moreover, humoral im-
mune responses against the WT1 protein could be eli-
cited in patients with WT1-expressing hematopoietic
malignancies [32]. Therefore, therapeutic vaccines direc-
ted against WT1 have the increased expectation that
they will be able to elicit and/or boost an immune re-
sponse to WT1. For example, an imatinib-treated patient
with CML who was intradermally administered a WT1
peptide vaccine elicited WT1-specific immune responses
and had a resultant reduction in persistent residual dis-
ease with the co-administration of imatinib. BCR-ABL
mRNA levels were maintained below the detection limit
for 8 months beginning at vaccination week 77. The de-
crease in BCR-ABL mRNA levels was associated with an
increase in the frequency of WT1-specific CTLs [33].
These findings indicated that WT1 peptide vaccines may
become a safe and cure-oriented treatment for patients
with CML who have residual disease despite imatinib
treatment.
Potential LAA vaccines
The BCR-ABL fusion peptide is the predominant antigen
in CML, and WT1 is also thought to be important
for the identification of leukemia-associated antigens
(LAAs) in CML to elicit a specific immune response in
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munotherapy with an optimal expression pattern is
required for patients with CML, and the identification
of additional LAAs is a pivotal step [34,35]. Recently,
a number of LAAs that are able to induce specific
immune responses were identified in CML including
telomerase, PR1, hyaluronan acid-mediated motility
(RHAMM), CML-66, CML-28, CML-Ag165, NM23-H2,
PPP2R5C, PR3, ELA2, PRAME and a novel epitope
derived from the M-phase phosphoprotein 11 protein
(MPP11) [34,36-42]. Most of these LAAs have been
recognized by human CD8+ T cells. Dendritic cells were
DCs pulsed with peptides and then used to generate
CTLs. Aurora-A kinase (Aur-A) is a member of the
serine/threonine kinase family that regulates the cell div-
ision process and has been recently implicated in
tumorigenesis. An antigenic 9-amino-acid epitope (Aur-
A (207–215): YLILEYAPL), which was derived from
Aur-A, is capable of generating leukemia-reactive CTLs
in the context of HLA-A*0201. Thus, cellular immuno-
therapy targeting Aur-A is a promising strategy for
leukemia therapy [43].
DC vaccines
DCs are professional antigen-presenting cells that play a
pivotal role in the induction of humoral and cellular im-
mune responses. In the past decade, there has been in-
creasing evidence that tumor antigen-loaded DCs are
able to elicit anti-tumor T cell responses. DCs from
healthy donors and patients with CML were confirmed
to be suitable for clinical application in DC-based im-
munotherapy protocols in numerous studies.
CML-derived DC vaccines
In CML, DCs and leukemic cells share common pro-
geny, leading to the constitutive expression of putative
tumor antigens, and up to 98% of myeloid DCs gener-
ated from peripheral blood mononuclear cells are BCR-
ABL positive. The ex vivo differentiation of myeloid
leukemic blasts into DCs holds significant promise for
use as cellular vaccines. CML-derived DCs (CML-DCs)
may have distinct deficiencies such as reduced migra-
tion, endocytosis, phagocytosis, antigen processing, DC
maturation and cytokine production. CML-DCs are also
defective for the processing and presentation of exogen-
ous antigens such as tetanus toxoid. The antigen-
processing defects may be a consequence of the reduced
capacity of CML-DCs to capture antigens via macropi-
nocytosis or mannose receptors when compared with
DCs generated from healthy individuals. This is due to
the PKC-induced differentiation associated with the
down-regulation of BCR-ABL activity, which raises the
possibility that CML-derived DC vaccines will be less ef-
fective in presenting leukemia-specific Ags [44]. The DCabnormalities in patients with CML may be abrogated by
the proper in vitro stimulation of leukemic DCs [45-47].
However, in 2006, a phase I immunotherapy CML trial
demonstrated that DC injections were well tolerated and
safe, while no clinical responses was found [48]. The in-
crease in T cell sensitivity to CML-specific stimulation
that accompanied active immunization by CML DCs
justifies further clinical studies, possibly with modifica-
tions such as an increased frequency and number of DC
injections. In an additional phase-I/II study, autologous
DCs were generated from peripheral blood monocytes
and used as a vaccine in patients with chronic phase
CML who had not achieved an adequate cytogenetic re-
sponse after IFN-α or imatinib treatment and demon-
strated that T cells that recognize leukemia-associated
antigens become detectable [49]. BCR-ABL-expressing
DCs appear to inefficiently to induce CML-specific T cell
responses resulting from low DC maturation and
impaired homing to secondary lymphoid organs. More-
over, BCR/ABL-expressing DCs in the thymus may con-
tribute to CML-specific tolerance induction for specific
CTLs [50].
Ag-loaded “artificial” DC vaccines
Based on the low efficiency of CML-derived DCs for in-
ducing CML–specific CTLs, antigen-loaded DC vaccines
may be a strategy to enhance the effects of DC vaccines
in CML. A recombinant adeno-associated virus vector
encoding the p210 (BCR-ABL) b3a2 variant fusion re-
gion with flanking sequences (CWRBA) was constructed
and used to express the BCR-ABL fusion region within
primary human DCs. CWRBA-transduced DCs elicited
cytotoxic CD4+/Th1 and CD8+ responses. Cytotoxicity
against a tumor cell line endogenously expressing the
p210 (BCR-ABL) b3a2 variant fusion region was also
demonstrated. Thus, this developed construct may serve
as a candidate vaccine for gene-based, antigen-specific
CML immunotherapy [51]. In a small trial, three
patients with CML received three series of four adminis-
trations of BCR-ABL peptide-pulsed DCs, and all
patients developed peptide-specific cellular immune
responses with no clinical response. Therefore, the clin-
ical benefits of BCR-ABL peptide-specific vaccinations
in CML remain to be determined [52]. Further vaccine
development is necessary to increase the clinical effect.
Recently, a pilot study was developed to determine
whether K562/GM-CSF vaccine immunotherapy could
improve clinical responses to imatinib in patients with
CML. Nineteen patients with chronic phase CML who
achieved at least a major cytogenetic response but had
persistent, measurable disease despite one or more years
on imatinib were eligible. Each patient was given a series
of four vaccines, which was administered in three-week
intervals, while remaining on a stable dose of imatinib.
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prove molecular responses in patients on imatinib, in-
cluding achieving complete molecular remission [53].
Moreover, the vaccine effect may be enhanced by cyto-
kines such as IL-12, GM-CSF [54].
Adoptive T-cell therapy
Adoptive antigen-specific immunotherapy is one of the
best approaches for tumor immunotherapy. Antigen-
specific CTLs can directly kill tumor cells while ignoring
the host immune status.
Donor leukocyte infusion
Donor leukocyte infusion (DLI) after marrow transplant-
ation has induced lasting remission in the majority of
patients with CML in hematological or cytogenetic re-
lapse. This effect also provided the first direct evidence
of the graft-versus-leukemia (GVL) effect after allogeneic
bone marrow transplantation (BMT) [55]. There is a
strong GVL of allogeneic stem cell transplantation (allo-
HSCT) effect due to the elimination of tumor cells by
alloimmune effector lymphocytes, which is used for the
prophylaxis of leukemia relapse and improvement of
transplantation outcomes [56,57].
DLI can be safely administered to patients relapsing
after unmodified, unrelated allografts, exerting an antil-
eukemic effect that is sufficiently potent for reversing
the accelerated disease phase. Moreover, DLI was also
used in patients with CML who were refractory to IFN-
α or imatinib, lacked donors for allo-HSCT, and received
autotransplants followed by the infusion of ex vivo costi-
mulated autologous T cells [58]. However, graft-versus-
host disease (GVHD) is a major complication of DLI.
One of the methods to control GVHD may be improved
using suicidal gene-modified T cells for DLI, allowing T-
cell elimination if severe GVHD develops [59]. If the
GVL effect could be separated from GVHD through the
adoptive transfer of selected T cells that recognize
leukemia-specific antigens or minor histocompatibility
antigens (miHAs), which are expressed predominantly
on hematopoietic cells, it may preclude an attack on
normal tissues. The GVL effect induced by DLI is
thought to be mediated by clonally expanding T cells
with different TCR Vβ repertoires in different patient
groups such as Vβ16 or Vβ21 [16,60]. The transient pro-
liferation of the limited number of T cells detected in
the peripheral blood 3–5 months after DLI probably
reflects the GVL response against CML cells and may
serve as a marker for the appearance of the GVL effect
induced by DLI [60].
Recently, in a BCR-ABL1 transduction/transplantation
mouse model for studying the DLI mechanisms in
MHC-matched, miHA-mismatched allogeneic chimeras
with CML-like leukemia, the GVL effect from DLI couldbe identified, and the GVL effect is directed against
miHAs shared by normal and leukemic stem cells, which
are predominantly mediated by CD8+ T cells with minor
contributions from CD5-splenocytes including nat-
ural killer cells. These results define a physiological
model of CML adoptive immunotherapy that will be
useful for investigating the GVL cellular and molecular
mechanisms [61].
CTL
Although DLI has been effective in patients with CML
relapsing after allo-HSCT, efforts to augment GVL and
immune reconstitution have been limited by GVHD.
One approach for augmenting GVL has been to infuse
ex vivo-generated T cells with defined specificities.
Different alternative approaches for specific adoptive
immunotherapy with CTLs targeted to different CML-
associated LAAs were reported including CD8+ T cells
from donors vaccinated against a single miHA expressed
by leukemia cells, PRAME CTLs, donor derived b2a2-
specific and b3a2-specific T cells, and Aur-A-specific
CTLs [43,62-66].
Recently, infusion using in vitro-generated donor T
cells reactive against peptides derived from CML-
associated antigens was reported in a trial with 14
patients with CML, who received conditioning therapy
followed by CD34+ selected HSCT from matched sib-
lings or unrelated donors. Donor-derived mature DCs
generated in vitro from CD14+ monocytes were loaded
with human leukocyte Ag-restricted peptides derived
from PR1, WT1, and/or BCR-ABL and used to repeti-
tively stimulate donor CD8+ T cells in the presence of
IL-2 and IL-7. Stimulated T cells were infused 28, 56,
and 112 days after transplantation. Thirteen patients sur-
vived and 7 remain in molecular remission (median fol-
low-up: 45 months). Importantly, all patients receiving
CD8+ T cells displaying marked cytotoxic activity
in vitro and detectable peptide-reactive CD8+ T cells
during follow-up have not experienced GVHD or re-
lapse. These results reveal that the prophylactic infusion
of allogeneic CD8+ T cells that are reactive against pep-
tides derived from CML-associated antigens is a safe and
promising therapeutic strategy [67].
In general, the most effective specific CTLs from DLI
were αβ + T cells that were HLA restricted. Increasing
data demonstrate that γδ + T cells play a critical role in
anti-leukemia after stem cell transplantation. Moreover,
γδ + T cells activated by phosphoantigens or agents that
induce their accumulation within cells e.g., zoledronate,
may represent a promising strategy for the design of a
novel and highly innovative immunotherapy capable of
overcoming imatinib resistance. Recently, an animal
study has demonstrated that Vγ9Vδ2 + T cells recognize
trogocytosis and efficiently kills imatinib-sensitive and
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dronate, and its cytotoxicity is largely dependent on the
granule exocytosis- and, partially, TRAIL-mediated path-
ways, was TCR-mediated and required isoprenoid bio-
synthesis by zoledronate-treated CML cells. Importantly,
Vγ9Vδ2 + T cells from patients with CML can be
induced by zoledronate to develop antitumor activity
against autologous and allogeneic zoledronate-treated
leukemia cells, both in vitro and when transferred into
immunodeficient mice in vivo. Therefore, this study may
indicate that the intentional activation of Vγ9Vδ2 T cells
by zoledronate may substantially increase their antileu-
kemia activities and represent a novel strategy for CML
immunotherapy [68].
T cell receptor gene modified T cells
Adoptive transfer of antigen-specific T cells is an
attractive immunotherapy method for hematological ma-
lignancies and cancer. The difficulty of isolating antigen-
specific T cells for individual patients limits the more
widespread use of adoptive T cell therapy. The demon-
stration that cloned T cell receptor (TCR) genes may be
used to produce T cell populations of desired specificity
offers new opportunities for antigen-specific T cell ther-
apy. In hematologic malignancies, TCR specificity for
WT1 peptides, a peptide from the EB virus, and a
DLBCL-associated antigen were transferred into donor
T cells and displayed specificity against tumor cells
expressing specific LAAs [69,70]. The first trial in
humans demonstrated that TCR gene-modified T cells
specific for the MART-1 protein persisted for an extended
time and reduced tumor burden in some patients. The
Strauss HJ research team isolated high avidity CTLs spe-
cific for a WT1-derived peptide presented by HLA-A2
and cloned the TCR α and β genes of a WT1-specific CTL
line. The genes were inserted into retroviral vectors for
the transduction of human peripheral blood T cells from
patients with leukemia and normal donors. While the
treatment of leukemia-bearing NOD/SCID mice with T
cells modified with a WT1-specific TCR eliminated
leukemia cells in the bone marrow of most mice, treat-
ment with T cells transduced with a TCR with irrelevant
specificity did not diminish the leukemia burden. The de-
velopment of new TCR gene constructs holds great prom-
ise for the safe and effective delivery of TCR gene therapy
for the treatment of malignancies [69]. The first phase I
clinical trial with TCR-modified CTLs was performed as a
melanoma therapy in 2006 [71], and WT1- and BCR-
ABL-specific TCR-modified CTLs have potential for CML
immunotherapy in future.
Alternatively, chimeric TCRs (chTCRs) comprising
single-chain variable fragments (scFvs) of murine anti-
bodies and human signaling molecules were used to re-
direct the specificity of autologous or allogeneic T cellsand were developed as novel therapeutic agents for
CML treatment. Wang D et al. engineered a scFv from
the CMA1 hybridoma cell line, which produces mono-
clonal antibodies that are specific against CML. The
genes encoding the heavy and light chain variable
regions were amplified from CMA1 cDNA, and a huma-
nized chTCR was constructed. The novel hchTCR spe-
cific for CML cells can be expressed, normally presented
on the cell surface, and may be used to redirect human
T cells [72].
Conclusions and future investigation
Data from vaccination and adoptive T cell immunother-
apy for CML have indicated that the immune system
may contribute to disease control in CML. Preliminary
data from specific TCR-modified T cells against CML
will have to be validated in well-designed clinical trials
with cells generated via reproducible methods and in
accredited structures working according to good manu-
facturing practices.
Based on the PD-1/PD-L1 expression feature in CML
cells and specific T cells for CML, blocking the PD-1/
PD-L1 interaction may restore the function of CML-
specific CTLs and represent a novel therapeutic ap-
proach for CML.
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